- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: CBP30 targets the CBP/p300 bromodomain, with much improved selectivity compared to the pan-BET bromodomain inhibitor (+)-JQ1 . CBP30 has therapeutic potential against autoimmune diseases characterised by aberrant Th17 responses.
This is a compound from the Structural Genomics Consortium's (SGC) Epigenetics Probes Collection.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Gallenkamp D, Gelato KA, Haendler B, Weinmann H. (2014)
Bromodomains and their pharmacological inhibitors.
ChemMedChem, 9 (3): 438-64. [PMID:24497428]
2. Hammitzsch A, Tallant C, Fedorov O, O'Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, Vecellio M et al.. (2015)
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Proc. Natl. Acad. Sci. U.S.A., 112 (34): 10768-73. [PMID:26261308]